Stock Market & Financial Investment News

News Breaks October 15, 2012 12:13 EDT BMY Bristol-Myers HCV combo treatment clears virus in 94% of patients in study In an abstract of a phase 2a, open-label study conducted with a regimen including a Bristol-Myers drug, researchers stated that a 12-week regimen of daclatasvir, asunaprevir, and BMS-791325 yielded "SVR4" of 94% in treatment-naive patients with genotype 1 Chronic Hepatitis C Virus, or HCV, infection. SVR4 is defined as no detectable hepatitis C virus four weeks after stopping therapy. The study's authors concluded: "Twelve weeks of the interferon- and ribavirin-free regimen of DCV + ASV + BMS-791325 was well tolerated and achieved a high rate of SVR4 in chronic HCV GT1-infected patients who were mainly GT1a and IL28B non-CC genotype. Further investigation of this regimen in the treatment of HCV is warranted." The abstract of the study was posted to the website of The American Association for the Study of Liver Diseases ahead of the organization's November annual meeting. News For BMY From The Last 14 Days Check below for free stories on BMY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 20, 2013 10:03 EDT BMY Shire advances after report renews takeover speculation Subscribe for More Information 06:30 EDT BMY Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. 06:25 EDT BMY Shire may return cash to thwart takeover, Daily Mail reports Subscribe for More Information May 17, 2013 13:21 EDT BMY Options with increasing implied volatility: CPRT BMY GDI HNZ Subscribe for More Information May 16, 2013 16:32 EDT BMY Bristol-Myers announces intention to voluntarily delist preferred stock Subscribe for More Information 13:20 EDT BMY Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. 13:14 EDT BMY Bristol-Myers upgraded to Outperform from Market Perform at Leerink Subscribe for More Information 08:55 EDT BMY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:38 EDT BMY Bristol-Myers shares likely to give back recent gains, says Leerink Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. 05:52 EDT BMY Stocks with implied volatility movement; BMY SLV Subscribe for More Information May 15, 2013 11:28 EDT BMY Options with increasing implied volatility: BMY AGNC EBIX IAU Subscribe for More Information 09:43 EDT BMY Active equity option families trading on open Subscribe for More Information May 14, 2013 07:24 EDT BMY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 10, 2013 11:48 EDT BMY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information May 9, 2013 10:17 EDT BMY Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 8, 2013 10:33 EDT BMY Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. May 6, 2013 17:03 EDT BMY Bristol-Myers, Pfizer announce publication of ARISTOTLE trial Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. Based on the results of the subanalysis, the benefits of Eliquis compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' quality of INR control. 08:53 EDT BMY BofA/Merrill's major pharma analysts hold an analyst/industry conference call Subscribe for More Information 07:27 EDT BMY Bristol-Myers, AstraZeneca announces results of metreleptin study Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.